NCT02971423View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

June 1, 2017

Study Completion Date

June 1, 2017

Conditions
Acinetobacter Baumannii Infection
Interventions
DRUG

ETX2514

DRUG

Placebo

matching placebo infusion

DRUG

Sulbactam

DRUG

Imipenem/Cilastatin

Trial Locations (1)

3004

Melbourne

Sponsors
All Listed Sponsors
lead

Entasis Therapeutics

INDUSTRY

NCT02971423 - Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects | Biotech Hunter | Biotech Hunter